76870-09-2

Basic information

• Product Name: AKOS BC-1990
• Synonyms: AKOS BC-1990;CHEMBRDG-BB 6570475;4-(2-MORPHOLIN-4-YL-2-OXOETHOXY)ANILINE;UKRORGSYN-BB BBV-099900;[4-(2-morpholin-4-yl-2-oxoethoxy)phenyl]amine;4-(2-morpholin-4-yl-2-oxoethoxy)aniline(SALTDATA: FREE);2-(4-aminophenoxy)-1-morpholin-4-ylethanone;2-(4-aminophenoxy)-1-morpholin-4-yl-ethanone
• CAS NO: 76870-09-2
• Molecular Formula: C₁₂H₁₆N₂O₃
• Molecular Weight: 236.269
• Mol File: 76870-09-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 479.7°C at 760 mmHg
• Flash Point: 243.9°C
• Appearance: /
• Density: 1.24g/cm³
• Vapor Pressure: 2.31E-09mmHg at 25°C
• Refractive Index: 1.579
• CAS DataBase Reference: AKOS BC-1990(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BC-1990(76870-09-2)
• EPA Substance Registry System: AKOS BC-1990(76870-09-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 76870-09-2(Hazardous Substances Data)

Usage

Description

AKOS BC-1990, with the chemical name 6,7-dimethoxy-4,5,6,7-tetrahydro-1-benzofuran-3-one, is a synthetic intermediate chemical compound characterized by its aromatic and oxygen-containing functional groups. It has a molecular formula of C18H20O6, a molecular weight of 332.34 g/mol, and is a solid at room temperature. AKOS BC-1990 serves as a building block in organic synthesis and is utilized as a research chemical in various laboratory experiments, playing a crucial role in the production of pharmaceuticals and other organic compounds.

Uses

Used in Pharmaceutical Industry:
AKOS BC-1990 is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique chemical structure and functional groups make it a valuable component in the synthesis of a wide range of medicinal compounds, contributing to the development of new and innovative treatments.
Used in Organic Synthesis:
AKOS BC-1990 is used as a building block in organic synthesis for the creation of various organic compounds. Its aromatic and oxygen-containing functional groups provide versatility in chemical reactions, allowing for the formation of a diverse array of molecules with potential applications in various industries.
Used in Research and Development:
AKOS BC-1990 is used as a research chemical in laboratory experiments, enabling scientists to explore its properties and potential applications. Its utilization in research and development contributes to the advancement of knowledge in the field of chemistry and the discovery of new compounds and materials with practical uses.

InChI:InChI=1/C12H16N2O3/c13-10-1-3-11(4-2-10)17-9-12(15)14-5-7-16-8-6-14/h1-4H,5-9,13H2

Upstream product

• 50508-33-3 1-(morpholin-4-yl)-2-(4-nitrophenoxy)ethanone 
• 20142-88-5 2-(4-nitrophenoxy)acetyl chloride 
• 1798-11-4 4-nitrophenoxyacetic acid 
• 19786-48-2 methyl 2-(4-nitrophenoxy)acetate 
• 19076-89-2 ethyl 4-nitrophenoxyacetate 
• 100-02-7 4-nitro-phenol 

Downstream Products

• 110506-65-5 2-(4-Isothiocyanato-phenoxy)-1-morpholin-4-yl-ethanone 

Relevant articles and documents

Diaryl urea compound as well as preparation method and pharmaceutical application thereof

The invention belongs to the field of medicinal chemistry, and discloses a novel diarylurea compound as shown in a formula (I), physiologically acceptable salts, solvates and crystal forms of the novel diarylurea compound, a preparation method of the comp

JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma

JAK3 is predominantly expressed in hematopoietic cells and has been a promising therapeutic target for the treatment of B-cell lymphoma. In this study, a new class of thieno[3,2-d]pyrimidines harboring acrylamide pharmacophore were synthesized as potent covalent JAK3 inhibitors (IC50 50 values of 1.9 nM and 1.8 nM, respectively. Furthermore, compared with the reference agents, Spebrutinib and Ibrutinib, 9a not only demonstrated enhanced antiproliferative activity against B lymphoma cells, but also showed very weak proliferative inhibition against normal peripheral blood mononuclear cells (PBMCs) at a concentration of 20 μM. Analysis of the mechanism revealed that 9a could induce the obvious apoptosis in B lymphoma cells and prevent JAK3-STAT3 cascade as well as BTK pathway. Taken together, 9a may be served as a potential new JAK3 inhibitor for the treatment of B-cell lymphoma.

(E)-3-(Aryl(arylamino)methylene)indolin-2-one derivatives: An efficient synthetic approach and evaluation of their cancer inhibitory activity

A series of (E)-3-(aryl(arylamino)methylene)indolin-2-one derivatives were synthesised using an efficient synthetic approach. The method involved reaction of 3-bromo-3-(bromo(aryl)methyl)indolin-2-one with substituted anilines through nucleophilic substitution and a simultaneous elimination using NaHCO3 in DMF. The anticancer activity of the products against four cell lines, HCT-116, A549, SKOV3 and MDA-MB-231, was also evaluated, and several compounds showed moderate inhibitory activity.